APA (7th ed.) Citation

F, J., G, D., JA, Z., C, S., S, D., E, D., . . . F, A. (2026). Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses. The journal of prevention of Alzheimer's disease, 13(8), 100605. https://doi.org/10.1016/j.tjpad.2026.100605

Chicago Style (17th ed.) Citation

F, Jessen, et al. "Efficacy and Safety of Donanemab in the European Eligible Population: TRAILBLAZER-ALZ 2 Post-hoc Analyses." The Journal of Prevention of Alzheimer's Disease 13, no. 8 (2026): 100605. https://doi.org/10.1016/j.tjpad.2026.100605.

MLA (9th ed.) Citation

F, Jessen, et al. "Efficacy and Safety of Donanemab in the European Eligible Population: TRAILBLAZER-ALZ 2 Post-hoc Analyses." The Journal of Prevention of Alzheimer's Disease, vol. 13, no. 8, 2026, p. 100605, https://doi.org/10.1016/j.tjpad.2026.100605.